Review

Therapeutic Role of Carotenoids in Blood Cancer: Mechanistic Insights and Therapeutic Potential

Yaseen Hussain 1,2, Abdullah 3, Khalaf F. Alsharif 4, Michael Aschner 5, Abdulrahman Theyab 6,7, Fazlullah Khan 8, Luciano Saso 9 and Haroon Khan 10,*

1 Lab of Controlled Release and Drug Delivery System, College of Pharmaceutical Sciences, Soochow University, Suzhou 215000, China; pharmycc@gmail.com
2 Department of Pharmacy, Bashir Institute of Health Sciences, Bharakahu, Islamabad 44000, Pakistan
3 Department of Pharmacy, University of Malakand, Chakdara 18800, Pakistan; abdullah@uom.edu.pk
4 Department of Clinical Laboratory, College of Applied Medical Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia; alsharif@tu.edu.sa
5 Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10463, USA; michael.aschner@einsteinmed.org
6 Department of Laboratory and Blood Bank, Security Forces Hospital, P.O. Box 14799, Mecca 21955, Saudi Arabia; aalshehri@sfhm.med.sa
7 College of Medicine, Al-Faisal University, P.O. Box 50927, Riyadh 11533, Saudi Arabia
8 Faculty of Pharmacy, Capital University of Science & Technology, Islamabad 44000, Pakistan; fazlullah.khan@cust.edu.pk
9 Department of Physiology and Pharmacology “Vittorio Ersperam”, Sapienza University, 00185 Rome, Italy; luciano.saso@uniroma1.it
10 Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan
* Correspondence: hkdr2006@gmail.com or haroonkhan@awkum.edu.pk

Abstract: Blood cancers are characterized by pathological disorders causing uncontrolled hematological cell division. Various strategies were previously explored for the treatment of blood cancers, including chemotherapy, Car-T therapy, targeting chimeric antigen receptors, and platelets therapy. However, all these therapies pose serious challenges that limit their use in blood cancer therapy, such as poor metabolism. Furthermore, the solubility and stability of anticancer drugs limit efficacy and bio-distribution and cause toxicity. The isolation and purification of natural killer cells during Car-T cell therapy is a major challenge. To cope with these challenges, treatment strategies from phyto-medicine scaffolds have been evaluated for blood cancer treatments. Carotenoids represent a versatile class of phytochemical that offer therapeutic efficacy in the treatment of cancer, and specifically blood cancer. Carotenoids, through various signaling pathways and mechanisms, such as the activation of AMPK, expression of autophagy biochemical markers (p62/LC3-II), activation of Keap1-Nrf2/EpRE/ARE signaling pathway, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), increased level of reactive oxygen species, cleaved poly (ADP-ribose) polymerase (c-PARP), c-caspase-3, -7, decreased level of Bcl-xL, cycle arrest at the G0/G1 phase, and decreasing STAT3 expression results in apoptosis induction and inhibition of cancer cell proliferation. This review article focuses the therapeutic potential of carotenoids in blood cancers, addressing various mechanisms and signaling pathways that mediate their therapeutic efficacy.

Keywords: carotenoids; blood cancer; challenges; carotenoids in blood cancer; therapeutic potentials

1. Introduction

Blood cancer is a group of disorders causing uncontrolled hematological cell division. Blood cancer classification into leukemia, myeloma and lymphoma, is based on the type of blood cell affected [1]. Leukemia is characterized by excessive and abnormal multiplication of leukocytes. It is sub-divided into acute and chronic, and includes acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid...
leukemia. Lymphoma is characterized by uncontrolled and abnormal lymphocyte production. The malignant lymphocytes travel through lymphatic system and blood to various organs where they accumulate to form tumors. Lymphoma is sub-divided into Hodgkin’s and Non-Hodgkin’s lymphoma based on the presence or absence of Reed-Sternberg cells, respectively. Myeloma is characterized by uncontrolled multiplication of plasma cells in the bone marrow. It is sub-divided into hyperdiploid and non-hyperdiploid myeloma based on whether the cancerous myeloma has more chromosomes or fewer chromosomes than normal, respectively. Non-hyperdiploid myeloma is more aggressive [1].

Leukemia is a common malignant disorder affecting millions of people across the globe. It is the 15th most commonly diagnosed cancer and the 11th cause of death due to malignancies [2]. Leukemia is universally encountered across the globe having higher prevalence in more developed countries. It has been estimated by the American Cancer Society that in the year 2020, that 178,520 individuals were to be diagnosed with leukemia, myeloma, and lymphoma in the United States (USA). In the USA, the prevalence and mortality of leukemia in males is higher than females [2]. Leukemia is malignant clonal disorder of the organs that produced the blood and involve one or more cell lines in the hematopoietic system. There is diffuse replacement of bone marrow by immature and undifferentiated hematopoietic cells with consequent reduction in the RBCs and thrombocytes in peripheral blood. Leukemia is classified into lymphoid, myeloid and mixed leukemia based on hematopoietic organs involved [3].

2. Carotenoids: An Overview

Carotenoids are a large group of plant secondary metabolites containing more than 1000 compounds. It is based on C-40 tetraterpenoids; however, C-30 and C-50 based carotenoids found in bacteria have been recently included in the group [4–6]. When two C20 geranyl-geranyldiphosphate molecules are linked together, they produce carotenoids. All carotenoid compounds contain a polyisoprenoid structure, a long conjugated chain of double bonds and an almost bilateral symmetry around the central double bond [7]. Carotenoids have been found in plants, animals, fungi, and bacteria. Several carotenoids are orange, red or yellow color pigments associated with chlorophylls in plants helping against photo-oxidation and enhancing photosynthesis [8]. Carotenoids are divided into two main classes based on the presence (xanthophylls) or absence of oxygen (carotenes). Examples of xanthophylls are zeaxanthin, fucoxanthin and neoxanthin while α- and β-carotene and lycopene belong to the carotene group [9]. These can also be classified into provitamin A and non-provitamin A groups. The former contain α- and β-carotene, and β-cryptoxanthin while the examples of the latter are lutein and zeaxanthin [10]. Other compounds such as apocarotenoids (e.g., retinoids, vitamin A, β-ionone and α-ionone aromatic volatile compounds) are also derived from carotenoids by oxidative cleavage using carotenoid cleavage dioxygenases [7]. Figure 1 shows the sources and classification of carotenoids [11].

Commonly, carotenoids are hydrophobic compounds having very low water solubility that act in hydrophobic areas of the cell. The attachment of polar functional groups to the polyene chain changes the carotenoids polarity, which not only changes their localization within the biomembranes, but also their interaction with several molecules [12].

Figure 2 shows the structures of a few representative carotenoids.
Humans and animals are unable to synthesize carotenoids, yet they are found in their bodies due to dietary intake of food containing carotenoids. These are fat-soluble compounds absorbed from the intestine. Carotenoids are transported by the chylomicrons.
from intestinal mucosa to blood via lymphatics for delivery to the tissues. In the plasma, these are then transported by the lipoproteins [13]. Carotenoids are delivered to extra hepatic tissues via the interaction of lipoprotein particles with receptors and the degradation by lipoprotein lipase [13–15]. In mammals, facilitated diffusion has been found recently to mediate carotenoids intestinal absorption [16]. Several carotenoids are precursors of vitamin A and many are efficient anticancer and antioxidants agents.

Scientists have shown great interest in carotenoids due to correlation between their blood concentration and reduced incidence of chronic diseases [17]. A meta-analysis recently showed that subjects taking α-carotene, β-carotene, and β-cryptoxanthin had lower mortality [18]. On the basis of these health benefits, a health index has been proposed, that states that people having less than 1 µM of total carotenoids plasma concentration are associated with significantly higher risk for chronic diseases [19].

The major health benefits of carotenoids are due to their antioxidant activity, anti-inflammatory activity, and immune system enhancement [20,21]. During the past two decades, the role of carotenoids in the treatment and prevention of cancer has been studied [22,23]. At the molecular level, carotenoids exert their anticancer activity via modulation of several signaling pathways including cell proliferation, cell cycle progression, metastasis, angiogenesis, and apoptosis [24]. Carotenoids alters metastasis via regulatory mechanisms including HIF-1α, glucose transporter 1 (GLUT-1), uPA, RhoGTPase (RhoA, Rac1, and Cdc42), MMPs, E-cadherin, surface glycoprotein CD44 and CXCR4, non-metastatic protein 23 homolog 1 (Nm23-H1), and TIMPs [24]. The molecular mechanism for the bioactivities of carotenoids is illustrated in Figure 3.

![Molecular Mechanism for bioactivities of Carotenoids](image)

**Figure 3.** Molecular Mechanism for bioactivities of Carotenoids.

### 3. Cancer and Metastasis

Metastasis is one of the hallmarks of cancer and a major cause of treatment failure [25,26]. Drug resistance to chemotherapy also leads to recurrence of cancer and metastasis [27]. In about 90% of cancer patients, metastasis is the main cause of death [26]. Although early
diagnosis or prevention increases the clinical outcomes, cancer is often unfortunately diagnosed in advanced stages when metastasis has occurred [28,29]. Thus, the early detection of metastatic cancer and proper therapeutic intervention is mandatory in the management of advanced cancer [30]. Metastasis involves local invasion, intravasation, extravasation, survival in circulation, and colonization [31] (Figure 4).

Figure 4. Various involved steps in metastasis: (A) local invasion, (B) Intravasation, (C) circulation in blood or lymphatic vessels, (D) extravasations, and (E) colonization and metastasis. Infiltration of cancer cells from a primary tumor to surrounding parenchyma take place and traverse through the blood vessel’s membrane.

Metastasis of solid tumors can be defined as the appearance of secondary tumors distant from the primary site. In case of leukemia (liquid tumors), widespread disease is diagnosed initially, and the exact location of origin (bone marrow, lymph node or spleen) usually remains unknown. In addition to this ambiguity, leukemic cells possess the intrinsic ability of motility, there is disagreement whether leukemia is a metastatic disease. Despite this controversy, leukemia possesses several properties of metastasizing solid tumor cells. These include derivation from mutant clone that has the disease-initiating ability [32–34], spread through a cascade of molecular events involving intravasation, extravasation and colonization of tissues [35–37], reproducible and specific patterns of organ involvement [38], adaptation to tissue microenvironment that is different from the primary one [13,14], and widespread disease progression [39,40].

Metastasis heterogeneity and the difference of secondary tumors from the primary tumor as well as additional changes at epigenetic and genetic level are the other obstacles in the treatment of cancer [26]. Carotenoids exert anticancer activity by metastasis modulation and regulation of several molecules and signaling pathways involved in metastasis including chronic inflammation, tumor microenvironment, genetic and epigenetic factors, extracellular matrix, epithelial-mesenchymal transition (EMT), and cancer stem cells [11].
This review article focuses on the therapeutic potential of carotenoids in blood cancer with emphasis on mechanistic insights.

4. Challenges in Blood Cancer Treatment

Chemotherapy is one of the treatment options for blood cancer, but unfortunately, it exerts many toxic effects on various organs, including heart, liver, kidney, and brain, to name a few [41]. Chemotherapy leads mortality and morbidity in cancer patients as the drugs have low specificity, and thus, affects any rapidly dividing cell whether cancerous or healthy. Poor metabolism, solubility, and stability of anticancer drugs pose the challenge of limited efficacy, bio-distribution, and toxicity. Therefore, development of highly specific drug with minimum/no toxicity and better pharmacokinetic properties is imperative in the treatment of blood cancer [42–47].

Chimeric antigen receptors have been introduced to natural killer cells that have the potential of causing selective cancer cell cytotoxicity and thus used in cellular immunotherapy [48]. In addition, Chimeric antigen receptor T (CAR-T therapy is a versatile approach in the field of oncology that has shown therapeutic benefits in leukemia and lymphoma [49]. CAR-T cell therapy is used in patients suffering from cancers that are difficult to treat, where chemotherapy is ineffective, or where the cancer returns. This therapy has unprecedented efficacy in B cell malignancy especially in anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia with up to a 90% complete remission rate [50]. However, certain challenges also exist during treatment of hematological cancers, such as the isolation and purification of natural killer cells is a big challenge. The transduction of primary natural killer cells triggers heterogeneous population with decreased expansion. In association, such transduction is complicated as well [51]. Moreover, the structural design of CARs should have an impact on Natural Killer (NK) cells to prevent the hindrance in the clinical application of CAR-NK treatment. Binding with antigens, CAR-NK cell activation and the immune synapses optimal formation are the factors affected by CAR-binding epitope position and the distance from the CAR-NK cell surface [52].

Platelets targeting in blood cancer is another big challenge in cancer therapy because the interlinking of specific platelet with particular hematological malignancy is still unknown [53]. In addition, the use of antiplatelet agents for cancer treatment is hampered by the lack of understanding of conditions involved in eliciting anti-inflammatory, anti-adhesive and anti-angiogenic and anti-mitogenic functions of platelets. The inflammatory process in physiological wound healing is mediated in a natural way which, in turn, switches ON/OFF the epithelial—mesenchymal transition and cell proliferation as well [54]. However, such regulation is abnormal in cancer and a pathogenic chronic wound-healing process is induced. In such scenario, the interaction of platelets with tumor cells for initiation of epithelial—mesenchymal transition remains unknown and poses a continued challenge in blood oncology [55]. It is noteworthy that pharmacological and genetic targeting of platelets might be a suitable strategy for mimicking T-cell therapy, providing opportunities for cancer immunotherapy optimization through inhibition of immune checkpoints molecule and platelets simultaneously [56].

Acute myeloid leukemia (AML) often relapses due to leukemic stem cells, which re-initiate malignancy, and are resistant to drugs [57]. In order to address this problem, patients undergo allogenic stem cell transplant. However, this method also has significant mortality and morbidity [58]. The diagnosis of myeloma is confirmed by bone marrow sampling. Young individuals can better tolerate biopsy but it is a challenging job in weak and geriatric patients with bleeding risk and underlying osteoporosis [59].

Prognosis of adult patients with acute lymphoblastic leukemia (ALL) and the treatment regimen carrying several toxicity risks [60,61]. Improvement of prognosis of such patients is a challenging task [62]. Hematopoietic stem cell transplantation is a method of treatment for such patients but this treatment has some difficulties including the donor source, multidrug resistance before and after transplant and the development of graft versus host disease [63–66]. Cancer immunotherapy is dominated by immune cells, but there are many challenges to its
application including production cost, preservation, and transport. Extracellular vesicle (EVs); nano-scaled vesicles naturally secreted by NK cells and many other cells are used to attack tumor cells, but the mechanism cell demise has yet to be clarified [48].

5. Carotenoids in Cancer

Given their dietary origin, phytochemicals are presumed as a safer treatment choice. Such dietary based phytochemicals are used to cope with various diseases including cancer [20]. Among these safer phytochemicals, carotenoids belong to the class of tetraterpenes that exhibit C_{40}H_{56} hydrocarbon skeleton followed by alternate single and double bond conjugation [67]. Carotenoids impart chemical reactivity and photochemical properties to plants [68]. The presence of lipophilic and hydrophobic compounds in the carotenoid structure pose it low water soluble class of phytochemicals [69]. Carotenoids are mainly classified into carotenes and xanthophylls that give characteristic color in yellow to red spectrum range [70].

For normal physiological processes body cannot synthesize carotenoids and thus have to be obtained from diet [71]. Seven hundred carotenoids have been identified thus far [72], among which 40 are available in human diet [73]. Within human diet the representative carotenoids are lycopene, α/β carotene and xanthophylls such as β-cryptoxanthin, lutein and zeaxanthin [74]. The representative carotenoids in human diet along with their sources are shown in Table 1.

| Carotenoid       | Diet Source                                                | Reference   |
|------------------|------------------------------------------------------------|-------------|
| β-Cryptoxanthin  | Pepper, papaya, oranges, tangerine                        | [75]        |
| Lycopene         | Water melon, tomatoes, pumpkin                             | [76,77]     |
| α-Carotene       | Carrots, green leafy vegetables, coleslaw, pumpkin         | [78,79]     |
| Lutein/zeaxanthin| Cucumber, pumpkin, celery, broccoli, spinach, egg, beans, pepper, grapes, melon, carrots, beans | [80,81]     |

The purified extract of lycopene was evaluated for its anticancer potential in prostate cancer cells. The sera collected from male subjects were investigated and results showed a significant down regulation of p53 and up regulation of BAX/Bcl-2 ratio, resulting in apoptosis [82]. Apart from apoptosis induction, lycopene has the ability to cause cell cycle arrest, suppression of proliferation and modulation of signaling pathways in prostate cancer cells [83]. In a randomized double blind placebo controlled trial lycopene at a dose of 30 mg/day showed a higher concentration in prostate tissue suggesting a clue for loading to prostate cancer tissues [84]. The human prostate cancer cells proliferation was affected by neoxanthin along with apoptosis induction and endogenous antioxidant signals activation [85].

The purified extract of lutein was investigated in MCF-7 breast cancer cell line and the proposed carotenoid significantly inhibited the cell viability. Furthermore, lutein induced apoptosis, suppressed cell survival and antioxidant signals that ultimately resulted in inhibition of breast cancer cell growth [86]. Similarly, lutein in combination with long non-coding RNA cancer susceptibility (CASC9) was evaluated for the antiproliferative activity in MCF-7 breast cancer cells. The proposed hybridized array was evaluated through rtPCR, MTT assay, and dual luciferase reporter studies. Results showed that lutein down regulated the expression of CASC9 and up regulated the expression of miR-590-3p that eventually resulted in inhibition of breast cancer proliferation [87]. Xiaoming et al. reported the significant anti-breast cancer potential of lutein. The mechanism invoked for its anticancer potential is increased production of reactive oxygen species in intracellular environment of triple negative breast cancer. Lutein was also shown to inhibit breast cancer cell growth [88]. The activation of Nrf2/ARE signaling pathway and blocking of NF-κB pathway was found as mechanistic ways for the treatment of human breast cancer through lutein [89]. Astaxanthin through increased reactive oxygen species generation and β-carotene through
increased Bax production showed synergistic effect towards the cytotoxic killing of estrogen receptor positive MCF-7 breast cancer cells and estrogen receptor negative breast cancer cells [90,91].

The mechanism and efficacy of lycopene, \( \beta \)-carotene and \( \beta \)-cryptoxanthin was evaluated in smoking-induced oxidative DNA damage in lung cancer cells. The cells were exposed to smoking and treated with proposed carotenoids at different doses. Results showed that carotenoids at high concentrations had prooxidant effects, while at low concentrations showed antioxidant effects [92]. Fucoxanthin carotenoid extracted from Laminaria japonica was investigated for its anticancer potential in lung cancer cells. Transwell and wound healing assays were used for the detection of invasion and migration of lung cancer cells, and western blotting was used for determination of signaling pathways and transitions. Lung metastatic tumor model was used for the in vivo activity of fucoxanthin. Lung cancer cell metastasis was suppressed by fucoxanthin and enhanced the sensitivity of lung cancer cells to Gefitinib [93].

Preclinical research has shown that carotenoids are interesting candidates for the treatment of multiple cancers targeting metastasis, migration, and cell invasion and therefore stand strong candidates for clinical studies in order ascertain their clinical potential. The anticancer potential of carotenoids both in vitro and in vivo is shown briefly in Table 2 along with their mechanism.

Table 2. Carotenoids and their anticancer potential.

| Carotenoids | Cancer Type   | Study Design                                                                 | Mechanism                                                                 | References |
|-------------|---------------|------------------------------------------------------------------------------|---------------------------------------------------------------------------|------------|
| Crocin      | Breast cancer | 4T1 mammary carcinoma cells injected to BALB/c mice                          | Inhibition of Wnt/\( \beta \)-catenin target genes                         | [94]       |
| Retinoic acid | Colon cancer | CT26 murine colon cancer cells                                               | Inhibition of nuclear factor-kB, vimentin, \( \beta \)-catenin and increased level of E-cadherin, gap junctions | [95]       |
| Zeaxanthin   | Uveal melanoma | C918 cultured uveal melanoma cells                                           | Decreased matrix metalloproteinase, invasion and migration                | [96]       |
| \( \beta \)-cryptoxanthin | Gastric cancer | SGC-7901 gastric cancer cells                                                | Apoptosis induction, reduction in AMP-activated protein kinases, and matrix metalloproteinase | [11]       |
| Fucoxanthin  | Lung cancer   | murine PC9 xenograft, A549 lung cancer cells                                | Inhibition of Snail family of zinc-finger transcription factors 1, fibronectin and increased level of tissue inhibitors of metalloproteinase | [93]       |
|              | Ovarian cancer | SKOV3 ovarian cancer cells                                                   | Decreased \( \beta \)-catenin, vimentin and vascular endothelial growth factor | [97]       |
| Lycopene     | Oral cancer   | Murine CAL-27 oral cancer xenograft                                          | Inhibition of migration and N-cadherin with elevation in E-cadherin, increased ROS generation, activation of p53 signaling, and increased HSP60 expression | [98]       |
| Lutein       | Breast cancer | Human breast cancer cells (MCF-7, MDA-MB-468)                               |                                                                           | [89]       |
| \( \beta \)-carotene | Leukemia      | U 937, HL-60 cell line                                                      | Antioxidant, apoptosis, Cell cycle arrest                                  | [99]       |

6. Carotenoids in Blood Cancer

6.1. Carotenoids in Leukemia

Chronic lymphocytic leukemia is the most frequent form of blood cancer in adult population [100]. The failure of conventional therapeutic approaches is attributed to the poor response of chronic lymphocytic leukemia to apoptosis resistance and inductive autophagy [101,102]. In this context, recently the effect of carotenoids extracted from pump-
kin on leukemia cell line was evaluated. Results of the study showed that compared to untreated cells, the carotenoid extract showed a 40% reduction in cell proliferation without any cytotoxicity. The modulation of autophagy flux and activation of AMPK were the observed mechanisms for delay in cell proliferation. In addition, the expression of autophagy biochemical markers i.e., p62/LC3-II, was significantly changed [103]. The anti-blood cancer activity of β-carotenones, such as bixin and capsanthin, was investigated in leukemia K562 cell line. The carotenoids in time- and dose-dependent manner, induced apoptosis, decreased cell viability, and disrupted cell cycle progression. Mechanistically, it was observed that carotenoids inhibited cell proliferation through activation of Keap1-Nrf2/EpRE/ARE signaling pathway [104]. Similarly, using the same cell line, Amir, et. al. investigated the anti-leukemic effect of carotenoid—lycopene, at different dose concentrations ranging from 0 to 100 µg/mL using nano technology scaffold, showing enhanced percentage of apoptotic cells along with significant cell growth inhibition [105]. Another study investigated the inhibition of cell growth in leukemia cell line after administration of carotenoid (β-cryptoxanthin) from nano platform [106].

Among marine carotenoids, heteronemin was explored in cytarabine resistant acute myeloid leukemia cells. The MTT assay results showed that heteronemin significantly sensitized HL-60 cells toward sub toxic doses of cytarabine and showed a synergistic toxicity profile. In association, heteronemin down regulated the activation of activator protein 1 (AP-1), c-myc, mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) showing effective anticancer potential of carotenoid in acute myeloid leukemia [107]. Fucoxanthin isolated from Ishige okamurea induced apoptosis in human leukemia through increased level of reactive oxygen species (ROS), cleaved poly (ADP-ribose) polymerase (c-PARP), c-caspase-3, -7, and decreased level of Bcl-xL at a dosing concentration of 7.5, 15 and 30 µg [108]. Siphonaxanthin is a green algae carotenoid and its antileukemic activity was investigated in human leukemia cell line. Results showed that Siphonaxanthin triggered anti-angiogenic effect via down-regulation of signal transduction by fibroblast growth factor receptor-1. Siphonaxanthin also induced apoptosis with a 2 fold higher cellular uptake as compared to Fucoxanthin [109]. It shows that application of carotenoid is an interesting strategy in coping with the consequences of leukemia.

Chronic myelogenous leukemia is a form of leukemia characterized by over production of white blood cells [110]. The cytotoxic effect of carotenoids extracted from Spirulina platensis was evaluated in chronic myelogenous leukemia cell line (K-562). The cells were treated with various concentrations of S. platensis extract i.e., 0.25–50 mg/mL for a period of 72 h. The IC$_{50}$ value was 4.64 mg/mL and significantly comparable with cyclophosphamide [111]. Fucoxanthin’s in vitro cytotoxicity alone and in combination with chemotherapy drugs, doxorubicin and imatinib, was evaluated in human chronic myelogenous leukemia cell lines (TK6 and K562). Doxorubicin decreased cell proliferation and viability in both cell lines; imatinib inhibited cell proliferation in K562 cell line and increased cytotoxicity in TK6 cells while Fucoxanthin decreased cell proliferation in both cell lines with elevated cytotoxicity against K562 cell line [112]. Another study showed cell growth inhibition and apoptosis induction in Jurkat human T-cell leukemia cell line by Crocin, secondary to increased Bax gene expression and inhibition of Bcl-2 [113]. Similarly, in vivo and in vitro studies in human leukemia cell line (HL-60) showed pro apoptotic and anti proliferative effects by Crocin through cell cycle arrest at the G0/G1 phase. In addition, Crocin in xenograft a mouse HL-60 cell line significantly increased Bax expression, reduced tumor weight/size and inhibited Bcl-2 expression [114]. Crocetin showed anti proliferative effect in promyelocytic leukemia HL-60 cell line [115].

6.2. Carotenoids in Lymphoma and Myeloma

Lymphoma is another type of blood cancer that appears in lymphatic system [116]. Findings of a meta-analysis suggested that higher intake of carotenoids, such as α-carotene, β-carotene and lutein, protected against lymphoma [117]. In a recent hospital-based case
control study 512 newly diagnosed non-Hodgkin’s lymphoma patients and 512 healthy control group the anti-lymphoma potential of carotenoids was evaluated. Carotenoids intake, such as lycopene, \( \alpha \), and \( \beta \)-carotene was shown to be inversely related to non-Hodgkin’s lymphoma. Furthermore, carotenoids reduced the risk of non-Hodgkin’s lymphoma particularly in smokers [118]. A recent meta-analysis study in 3228 cases of non-Hodgkin’s lymphoma patients showed that \( \alpha \)-carotene (RR = 0.87, 95% CI = 0.78–0.97), \( \beta \)-carotene (RR = 0.80, 95% CI = 0.68–0.94) and lutein/zeaxanthin (RR = 0.82, 95% CI = 0.69–0.97) significantly decreased the risk of non-Hodgkin’s lymphoma. Data from preclinical studies confirmed that carotenoids had protective effects against non-Hodgkin’s lymphoma by increasing antioxidant and antiapoptotic activity [22].

Myeloma is blood cancer type that originates from plasma cells of bone marrow [119]. Crocin was shown to significantly reduce the production of reactive oxygen species along with anti-myeloma effect in U266B1 myeloma cell line [120]. Multiple myeloma is associated with abnormal or higher expression of STAT3 [121]. In this context, Raza et al. showed that astaxanthin decreased STAT3 expression leading to inhibition of DU145 cells proliferation [122].

7. Discussion

Blood cancer is a group of pathological disorders causing uncontrolled hematological cells division, starting in the bone marrow and spreading throughout the body. Blood cancer is classified into leukemia, myeloma and lymphoma based on the type of blood cell affected. Scientists have shown great interest in carotenoids due to correlation between blood concentration level and reduced incidence of chronic diseases. It has been demonstrated that people with high blood concentration of \( \beta \)-carotene have decreased incidence of all-cause mortality in comparison to those having low blood concentration.

Chemotherapy in blood cancer therapy have posed many adverse consequences and unfortunately failed in blood cancer therapy. Such failure is one among major challenges for researcher working on blood cancer. Chimeric antigen receptors and CAR-T cell therapy have shown therapeutic benefits in blood cancer therapy, however, the isolation, purification, and transduction of natural killer cells for such therapies is quiet challenging. In addition, platelets targeting in blood cancer is another big challenge because the interlinking of specific platelet with particular hematological malignancy remains unknown. Similarly, the introduction of anti–platelet agents for cancer treatment is hampered by the lack of understanding on conditions involved in eliciting of anti-inflammatory, adhesive and anti-angiogenic and mitogenic functions of platelets. The interaction between platelets and tumor cell for triggering epithelial to mesenchymal transition remains unknown. Relapse and drug resistance during blood cancer therapy pose other challenges. Phytochemicals due to the dietary origin are presumed as a safer choice and thanks to their low toxicity. Such dietary based phytochemicals are used to treat several diseases including cancer. Among these safer phytochemicals, carotenoids belong to the class of tetraterpenes that impart chemical reactivity and photochemical properties to plants. Multiple carotenoids such as lycopene, lutein, astaxanthin, \( \beta \)-carotene, \( \beta \)-cryptoxanthin, crocin, zeaxanthin, and fucoxanthin were explored in various cancers that resulted in significant anticancer efficacy following different signaling pathways. Specifically, carotenoids were also evaluated in blood cancer including leukemia, lymphoma, and myeloma. It was revealed that chemotherapy failure in blood cancer due to poor response to apoptosis resistance and inductive autophagy was significantly improved through the use of carotenoids. Multiple research studies on carotenoids have shown that the therapeutic potential of carotenoids in blood cancer is attributed to various mechanisms such as activation of AMPK, expression of autophagy biochemical markers (p62/LC3-II), activation of Keap1-Nrf2/EpRE/ARE signaling pathway, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\( \kappa \)B), increased level of reactive oxygen species, cleaved poly (ADP-ribose) polymerase (c-PARP), c-caspase-3,-7, decreased level of Bcl-xL, cycle arrest at the G0/G1 phase and decreasing STAT3 expression. The targeting of mentioned signaling pathways and mechanisms has
opened new avenues in blood cancer therapy however need further exploration in the arena of blood cancer to overcome barriers in blood cancer therapy. The potential preclinical studies suggested that these molecules needed to be explored in clinical settings for possible new effective therapeutics.

8. Conclusions

It is concluded that carotenoids are a versatile class of phytochemicals which have been explored for targeting various cancers. However, in the arena of blood cancer it has been evaluated as an alternative therapy approach due to its potential of overcoming the challenges associated with blood cancer treatment particularly chemotherapy. Carotenoids through various signaling pathways and mechanism such as activation of AMPK, expression of autophagy biochemical markers (p62/LC3-II), activation of Keap1-Nrf2/EpRE/ARE signaling pathway, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), increased level of reactive oxygen species, cleaved poly (ADP-ribose) polymerase (c-PARP), c-caspase-3,-7, decreased level of Bcl-xL, cycle arrest at the G0/G1 phase and decreasing STAT3 expression results in apoptosis induction and inhibition of cancer cell proliferation. It best explains the mechanistic insights behind the particular blood cancer type therapy. It is to worth mention that the literature on carotenoids targeting blood cancer is still not enough and needs more exploration to find out more and new horizons in the blood cancer therapy for the improvement of blood cancer patient life quality. Furthermore, clinical trials on carotenoids significantly could left up it from bench top to the markets.

Author Contributions: Y.H., A., K.F.A., A.T. and F.K. have written different chapters of the review. M.A., L.S. and H.K. have designed, supervised and finalized the overall article. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bogeska, R. Focus on blood cancers and liquid biopsy research. Mol. Oncol. 2021, 15, 2251. [CrossRef] [PubMed]
2. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]
3. Tebbi, C. Etiology of acute leukemia: A review. Cancer 2021, 13, 2256. [CrossRef] [PubMed]
4. Umeno, D.; Tobias, A.V.; Arnold, F. Evolution of the C30 carotenoid synthase CrtM for function in a C40 pathway. J. Bacteriol. 2002, 184, 6690–6699. [CrossRef]
5. Giuffrida, D.; Sutthiwong, N.; Dugo, P.; Donato, P.; Cacciola, F.; Girard-Valenciennes, E.; Le Mao, Y.; Monnet, C.; Fouillaud, M.; Caro, Y. Characterisation of the C50 carotenoids produced by strains of the cheese-ripening bacterium Arthrobacter arilaitensis. Int. Dairy J. 2016, 55, 10–16. [CrossRef]
6. Yabuzaki, J. Carotenoids Database: Structures, chemical fingerprints and distribution among organisms. Database 2017, 2017, bax004. [CrossRef]
7. Saini, R.K.; Nile, S.H.; Park, S.W. Carotenoids from fruits and vegetables: Chemistry, analysis, occurrence, bioavailability and biological activities. Food Res. Int. 2015, 76, 735–750. [CrossRef]
8. Najib, M.Z.B.M. Biogranule Containing Photosynthetic Bacteria for Carbon Dioxide Reduction in Palm Oil Mill Effluent Treatment. Ph.D. Thesis, Universiti Teknologi Malaysia, Skudai, Malaysia, June 2017.
9. Amarowicz, R. Lycopene as a Natural Antioxidant; Wiley Online Library: Weinheim, Germany, 2011; Volume 113, pp. 675–677.
10. Stahl, W.; Sies, H.J. Bioactivity and protective effects of natural carotenoids. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2005, 1740, 101–107. [CrossRef]
11. Koklesova, L.; Liskova, A.; Samec, M.; Zhai, K.; Abotaleb, M.; Ashrafizadeh, M.; Brockmueller, A.; Shakibaei, M.; Biringer, K.; Bugos, O.J.B. Carotenoids in cancer metastasis—Status quo and outlook. Eur. J. Med. Chem. 2020, 10, 1653. [CrossRef]
12. Jomova, K.; Valko, M.J. Health protective effects of carotenoids and their interactions with other biological antioxidants. FASEB J. 2013, 70, 102–110. [CrossRef]
41. Naidu, M.U.R.; Ramana, G.V.; Rani, P.U.; Suman, A.; Roy, P. Chemotherapy-induced and/or radiation therapy-induced oral mucositis-complicating the treatment of cancer. *Neoplasia* **2004**, *6*, 423–431. [CrossRef]

42. Vagace, J.M.; Gervasini, G. *Chemotherapy Toxicity in Patients with Acute Leukemia*; Intechopen: London, UK, 2011.

43. Bae, Y.H. Drug targeting and tumor heterogeneity. *J. Control. Release* **2009**, *133*, 2. [CrossRef]

44. Bae, S.; Ma, K.; Kim, T.H.; Lee, E.S.; Oh, K.T.; Park, E.-S.; Lee, K.C.; Youn, Y.S. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. *Biomaterials* **2012**, *33*, 1536–1546. [CrossRef]

45. De Palma, M.; Venneri, M.A.; Roca, C.; Naldini, L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. *Nat. Med.* **2003**, *9*, 789–795. [CrossRef]

46. Navya, P.; Kaphle, A.; Daima, H. Nanomedicine in sensing, delivery, imaging and tissue engineering: Advances, opportunities and challenges. In *Nanoscience*; The Royal Society of Chemistry: Cambridge, UK, 2018; pp. 30–56.

47. Liu, J.; Charles Lin, P.; Zhou, B.P. Inflammation fuels tumor progress and metastasis. *Curr. Pharm. Des.* **2015**, *21*, 3032–3040. [CrossRef]

48. Revia, R.A.; Zhang, M. Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: Recent advances. *Mater. Today* **2016**, *19*, 157–168. [CrossRef]

49. Hu, W.; Wang, G.; Huang, D.; Sui, M.; Xu, Y. Cancer immunotherapy based on natural killer cells: Current progress and new opportunities. *Front. Immunol.* **2019**, *10*, 1205. [CrossRef]

50. Wang, Z.; Wu, Z.; Liu, Y.; Han, W.J. New development in CAR-T cell therapy for tumour immunotherapy. *Biosci. Rep.* **2017**, *37*. [CrossRef]

51. Dana, H.; Chalbatani, G.M.; Jalali, S.A.; Mirzaei, H.R.; Grupp, S.A.; Suarez, E.R.; Raposo, C.; Webster, T.J. CAR-T cells: Early successes in blood cancer and challenges in solid tumors. *Acta Pharmac. Sin. B* **2021**, *11*, 1129–1147. [CrossRef]

52. Zhang, C.; Oberoi, P.; Oelsen, S.; Waldmann, A.; Lindner, A.; Tonn, T.; Wels, W.S. Chimeric antigen receptor-engineered NK-92 cells: An off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. *Front. Immunol.* **2017**, *8*, 533. [CrossRef]

53. Huong, P.T.; Nguyen, L.T.; Nguyen, X.-B.; Lee, S.K.; Bach, D.-H. The role of platelets in the tumor-microenvironment and the drug resistance of cancer cells. *Cancers* **2019**, *11*, 240. [CrossRef]

54. Liu, J.; Charles Lin, P.; Zhou, B.P. Inflammation fuels tumor progress and metastasis. *Curr. Pharm. Des.* **2015**, *21*, 3032–3040. [CrossRef]

55. Labelle, M.; Begum, S.; Hynes, R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. *Cancer Cell* **2011**, *20*, 576–590. [CrossRef]

56. Rachidi, S.; Metelli, A.; Riesenberg, B.; Wu, B.X.; Nelson, M.H.; Wallace, C.; Paulos, C.M.; Rubinstein, M.P.; Garrett-Mayer, E.; Henning, M.; et al. Platelets subvert T cell immunity against cancer via GARP-TGF-β axis. *Sci. Immunol.* **2017**, *2*, eaai7911. [CrossRef]

57. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. *Nature* **2001**, *414*, 105–111. [CrossRef]

58. Chapuis, A.G.; Egan, D.N.; Bar, M.; Schmitt, T.M.; McAfee, M.S.; Paulson, K.G.; Voillet, V.; Gottardo, R.; Ragnarsson, G.B.; Bleakley, M.; et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. *Nat. Med.* **2019**, *25*, 1064–1072. [CrossRef]

59. Sonneveld, P.; Avet-Loiseau, H.; Lionia, S.; Usmani, S.; Siegel, D.; Anderson, M.K.; Chng, W.-J.; Moreau, P.; Attal, M.; Kyle, R.A.; et al. Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. *J. Am. Soc. Hematol.* **2016**, *127*, 2955–2962. [CrossRef]

60. Hunger, S.P.; Lu, X.; Devidas, M.; Camitta, B.M.; Gaynon, P.; Reaman, G.H.; Carroll, W.L. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children’s oncology group. *J. Clin. Oncol.* **2014**, *30*, 1663. [CrossRef]

61. Thomas, X.; Boiron, J.-M.; Huguet, F.; Dombret, H.; Bradstock, K.; Vey, N.; Kovacsovics, T.; Delannoy, A.; Fegueux, N.; Fenaux, P.; et al. Outcome of treatment in adults with acute lymphoblastic leukaemia: Analysis of the LALA-94 trial. *J. Clin. Oncol.* **2004**, *22*, 4075–4086. [CrossRef]

62. Levine, S.R.; McNeer, J.; Isakoff, M.S. Challenges faced in the treatment of acute lymphoblastic leukaemia in adolescents and young adults. *Clin. Oncol. Adolesc Young Adults* **2016**, *6*, 11–20.

63. Bar, M.; Wood, B.L.; Radich, J.P.; Doney, K.C.; Woolfrey, A.E.; Delaney, C.; Appelbaum, F.R.; Gooley, T. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. *Leuk. Res. Treat.* **2014**, *2014*, 1–9. [CrossRef]

64. Holtick, U.; Albrecht, M.; Chemnitz, J.M.; Theurich, S.; Skoetz, N.; Scheid, C.; von Bergwelt-Baildon, M. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. *Cochrane Database Syst. Rev.* **2014**, *4*. [CrossRef]

65. Pulsipher, M.A.; Langholz, B.; Wall, D.A.; Schultz, K.R.; Bunin, N.; Carroll, W.; Raetz, E.; Gardner, S.; Goyal, R.K.; Gastier-Foster, J.; et al. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: For whom and when should interventions be tested? *Bone Marrow Transplant.* **2015**, *50*, 1173–1179. [CrossRef]
66. Pulsipher, M.A.; Langholz, B.; Wall, D.A.; Schultz, K.R.; Bunin, N.; Carroll, W.L.; Raetz, E.; Gardner, S.; Gastier-Foster, J.M.; Howrie, D.; et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: A phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. J. Am. Soc. Hematol. 2014, 123, 2017-2025. [CrossRef] [PubMed]

67. Saini, R.K.; Sivanesan, I.; Keum, Y.-S. Emerging roles of carotenoids in the survival and adaptations of microbes. Indian J. Microbiol. 2019, 59, 125-127. [CrossRef] [PubMed]

68. Zia-Ul-Haq, M. Historical and introductory aspects of carotenoids. In Carotenoids: Structure and Function in the Human Body; Springer: Berlin/Heidelberg, Germany, 2021; pp. 1-42.

69. Langi, P.; Kiokias, S.; Varzakas, T.; Proestos, C. Carotenoids: From plants to food and feed industries. Crit. Rev. Food Sci. Nutr. 2021, 62, 1-25. [CrossRef] [PubMed]

70. Karmakar, A.; Das, A.K.; Ghosh, S.; Sil, P.C. Carotenoids as Coloring Agents. In Carotenoids: Structure and Function in the Human Body; Springer: Berlin/Heidelberg, Germany, 2021; pp. 189-207.

71. Zhang, Y.; Zhang, T.; Liang, Y.; Sui, X. Dietary bioactive lipids: A review on absorption, metabolism, and health properties. J. Agric. Food Chem. 2021, 69, 8929-8943. [CrossRef]

72. Singh, A.; Mukherjee, T. Application of carotenoids in sustainable energy and green electronics. Mater. Adv. 2022, 3, 1341-1358. [CrossRef]

73. Shahidi, F.; Pan, Y. Influence of food matrix and food processing on the chemical interaction and bioaccessibility of dietary phytochemicals: A review. Crit. Rev. Food Sci. Nutr. 2021, 62, 1-25. [CrossRef] [PubMed]

74. Diep, T.T.; Pook, C.; Rush, E.C.; Yoo, M.J.Y. Quantification of carotenoids, α-tocopherol, and ascorbic acid in amber, mulligan, and Laird’s large cultivars of New Zealand tamarillos (Solanum betaceum Cav.). Foods 2020, 9, 769. [CrossRef]

75. Jiao, Y.; Reuss, L.; Wang, Y. β-Cryptoxanthin: Chemistry, occurrence, and potential health benefits. Curr. Pharmacol. Rep. 2019, 5, 20-34. [CrossRef]

76. Khan, U.M.; Sevindik, M.; Zarrabi, A.; Nami, M.; Ozdemir, B.; Kaplan, D.N.; Selamoglu, Z.; Hasan, M.; Kumar, M.; Alshehri, M.M.; et al. Lycopene: Food sources, biological activities, and human health benefits. Oxidative Med. Cell. Longev. 2021, 2021, 2713511. [CrossRef]

77. Xavier, A.A.O.; Poy, B.; Óñez-García, E.; Carvajal-Lérida, I.; Jarén-Galán, M.; Garrido-Fernández, J.; Pérez-Gálvez, A.; Hornero-Méndez, D. Carotenoids bioavailability from foods: From plant pigments to efficient biological activities. Food Res. Int. 2012, 46, 438-450. [CrossRef]

78. Arballo, J.; Amengual, J.; Erdman, J.W. Lycopene: A critical review of digestion, absorption, metabolism, and excretion. Antioxidants 2021, 10, 342. [CrossRef]

79. Pieyrache, K.; Nipawan, K.; Chadapon, C.; Dahuwan, S.; Kunjana, R. Effect of drying on zeaxanthin content in vegetables and its application for vegetable seasoning. In E3S Web of Conferences; EDP Sciences: Les Ulis, France, 2020; p. 02007.

80. Óñez-García, E.; Carvajal-Lérida, I.; Jarén-Galán, M.; Garrido-Fernández, J.; Pérez-Gálvez, A.; Hornero-Méndez, D. Carotenoids bioavailability from foods: From plant pigments to efficient biological activities. Food Res. Int. 2012, 46, 438-450. [CrossRef]

81. Homero-Méndez, D.; Cerrillo, I.; Ortega, Á.; Rodríguez-Griñolo, M.-R.; Escudero-López, B.; Martín, F.; Fernández-Pachón, M.-S. β-Cryptoxanthin is more bioavailable in humans from fermented orange juice than from orange juice. Food Chem. 2018, 262, 215-220. [CrossRef]

82. Talvas, J.; Caris-Veyrat, C.; Guy, L.; Rambeau, M.; Lyan, B.; Minet-Quinard, R.; Lobaccaro, J.-M.A.; Vasson, M.-P.; George, S.; Mazur, A.; et al. Differential effects of lycopene consumed in tomato paste and lycopene in the form of a purified extract on target genes of cancer prostatic cells. Am. J. Clin. Nutr. 2010, 91, 1716–1724. [CrossRef]

83. Mirahmadi, M.; Azimi-Hashemi, S.; Saburi, E.; Kamali, H.; Pishbin, M.; Hadizadeh, F. Potential inhibitory effect of lycopene on prostate cancer. Biomed. Pharmacother. 2020, 129, 110459. [CrossRef]

84. Van Bremeen, R.B.; Sharifi, R.; Viana, M.; Pajkovic, N.; Zhu, D.; Yuan, L.; Yang, Y.; Bowen, P.E.; Stacewicz-Sapuntzakis, M. Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: A randomized, controlled trial. Cancer Prev. Res. 2011, 4, 711–718. [CrossRef]

85. Udayawara Rudresh, D.; Maradagi, T.; Stephen, N.M.; Niraikulam, A.; Nambi Ramudu, K.; Ponesakkı, G. Neoxanthin prevents H2O2-induced cytotoxicity in HepG2 cells by activating endogenous antioxidant signals and suppressing apoptosis signals. Mol. Biol. Rep. 2021, 48, 6923–6934. [CrossRef]

86. Kavalappa, Y.P.; Gopal, S.S.; Ponesakkı, G. Lutein inhibits breast cancer cell growth by suppressing antioxidant and cell survival signals and induces apoptosis. J. Cell. Physiol. 2021, 236, 1798–1809. [CrossRef]

87. Zhang, Y.; Chang, J.; Jiang, W.; Ye, X.; Zhang, S. Long non-coding RNA CASC9/microRNA-590-3p axis participates in lutein-mediated suppression of breast cancer cell proliferation. Oncol. Lett. 2021, 22, 544. [CrossRef]

88. Gong, X.; Smith, J.R.; Swanson, H.M.; Rubin, L. Carotenoid lutein selectively inhibits breast cancer cell growth and potentiates the effect of chemotherapeutic agents through ROS-mediated mechanisms. Molecules 2018, 23, 905. [CrossRef]

89. Chang, J.; Zhang, Y.; Li, Y.; Lu, K.; Shen, Y.; Guo, Y.; Qi, Q.; Wang, M.; Zhang, S. Nrf2/ARE and NF-kB pathway regulation may be the mechanism for lutein inhibition of human breast cancer cell. Future Oncol. 2018, 14, 719–726. [CrossRef]
90. Vijay, K.; Sowmya, P.R.-R.; Arathi, B.P.; Shilpa, S.; Shwetha, H.J.; Raju, M.; Baskaran, V.; Lakshminarayana, R. Low-dose doxorubicin with carotenoids selectively alters redox status and upregulates oxidative stress-mediated apoptosis in breast cancer cells. *Food Chem. Toxicol.* 2018, 118, 675–690. [CrossRef]

91. Shin, J.; Song, M.-H.; Oh, J.-W.; Keum, Y.-S.; Saini, R.K. Pro-oxidant actions of carotenoids in triggering apoptosis of cancer cells: A review of emerging evidence. *Antioxidants* 2020, 9, 532. [CrossRef]

92. Cheng, J.; Miller, B.; Eroglu, A. The Efficacy of Carotenoids in DNA Repair in Lung Cancer. *Curr. Dev. Nutr.* 2020, 4, 99. [CrossRef]

93. Ming, J.X.; Wang, Z.C.; Huang, Y.; Ohishi, H.; Wu, R.J.; Shao, Y.; Wang, H.; Qin, M.Y.; Wu, Z.L.; Li, Y.Y.; et al. Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib. *J. Ethnopharmacol.* 2021, 265, 113302. [CrossRef]

94. Arzi, L.; Hoshyar, R.; Jafarzadeh, N.; Riazi, G.; Sadeghizadeh, M. Anti-metastatic properties of a potent herbal combination in cell and mice models of triple negative breast cancer. *Life Sci.* 2020, 243, 117245. [CrossRef] [PubMed]

95. Shi, G.; Zheng, X.; Xu, X.; Wang, S.; Wang, Y.; Xing, F. All-trans retinoic acid reverses epithelial-mesenchymal transition in paclitaxel-resistant cells by inhibiting nuclear factor kappa B and upregulating gap junctions. *Cancer Sci.* 2019, 110, 379–388. [CrossRef]

96. Garg, S.; Afzal, S.; Elwakeel, A.; Sharma, D.; Radhakrishnan, N.; Dhanjal, J.K.; Sundar, D.; Kaul, S.C.; Wadhwa, R. Marine carotenoid fucoxanthin possesses anti-metastasis activity: Molecular evidence. *Mar. Drugs* 2019, 17, 338. [CrossRef] [PubMed]

97. Wang, R.; Lu, X.; Yu, R. Lycopene inhibits epithelial–mesenchymal transition and promotes apoptosis in oral cancer via PI3K/akt/m-TOR signal pathway. *Drag. Des. Dev. Ther.* 2020, 14, 2461. [CrossRef] [PubMed]

98. Upadhyaya, K.; Radha, K.; Madhyastha, H. Cell cycle regulation and induction of apoptosis by β-carotene in U937 and HL-60 leukemia cells. *BMB Rep.* 2007, 40, 1009–1015. [CrossRef]

99. Bi, M.-C.; Hose, N.; Xu, C.-L.; Zhang, C.; Sassoon, J.; Song, E. Nonlethal levels of zeaxanthin inhibit cell migration, invasion, and secretion of MMP-2 via NF-κB pathway in cultured human uveal melanoma cells. *J. Ophthalmol.* 2016, 2016, 8734309. [CrossRef] [PubMed]

100. Gomes, L.C.; Ferrão, A.M.L.; Evangelista, F.C.G.; de Almeida, T.D.; Barbosa, R.C.; das Graças Carvalho, M.; de Paula Sabino, A. Advances in chronic lymphocytic leukemia pharmacotherapy. *Biomed. Pharmacother.* 2018, 97, 349–358. [CrossRef]

101. Smith, L.D.; Minton, A.R.; Blunt, M.D.; Karydis, L.I.; Dutton, D.A.; Rogers-Broadway, K.-R.; Dobson, R.; Liu, R.; Norster, F.; Hogg, E.; et al. BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. *Leukemia* 2020, 34, 640–644. [CrossRef]

102. Moccia, S.; Russo, M.; Durante, M.; Lenucci, M.S.; Mita, G.; Russo, G.L. A carotenoid-enriched extract from pumpkin delays cell proliferation in a human chronic lymphocytic leukemia cell line through the modulation of autophagic flux. *Curr. Res. Biotechnol.* 2020, 2, 74–82. [CrossRef]

103. Zhang, X.; Zhao, W.-E.; Hu, L.; Zhao, L.; Huang, J. Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARγ) in K562 cancer cells. *Arch. Biochem. Biophys.* 2011, 512, 96–106. [CrossRef]

104. Almeida, T.P.; Ramos, A.A.; Ferreira, J.; Azqueta, A.; Rocha, E. Bioactive compounds from seaweed with anti-leukemic activity: A mini-review on carotenoids and phlorotannins. *Mini Rev. Med. Chem. 2020, 20*, 39–53. [CrossRef]

105. Gharib, A.; Faezizzadeh, Z.; Godarzee, M. Preparation and characterization of nanoliposomal beta-cryptoxanthin and its effect on proliferation and apoptosis in human leukemia cell line K562. *Trop. J. Pharm. Res.* 2015, 14, 187–194. [CrossRef]

106. Saikia, M.; Retnakumari, A.P.; Anwar, S.; Anto, N.P.; Mittal, R.; Shah, S.; Pillai, K.S.; Balachandran, V.S.; Peter, V.; Thomas, R.; et al. Heteronemin, a marine natural product, sensitizes acute myeloid leukemia cells towards cytarabine chemotherapy by regulating farnesyltransferase of Ras. *Oncotarget* 2018, 9, 18115. [CrossRef]

107. Hwang, D.; Kim, M.; Park, H.; Jeong, M.I.; Jung, W.; Kim, B. Natural products and acute myeloid leukemia: A review highlighting mechanisms of action. *Nutrients* 2019, 11, 1010. [CrossRef]

108. Sugawara, T.; Ganesan, P.; Li, Z.; Manabe, Y.; Hirata, T. Siphonaxanthin, a green algal carotenoid, as a novel functional compound. *Drug Des. Dev. Ther.* 2020, 14, 3660–3668. [CrossRef]

109. Kenzik, K.M.; Bhatia, R.; Williams, G.R.; Bhatia, S. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. *Cancer 2019*, 125, 2570–2578. [CrossRef]

110. Hernandez, F.Y.F.; Khandual, S.; López, I.G.R. Cytotoxic effect of Spirulina platensis extracts on human acute leukemia Kasumi-1 and chronic myelogenous leukemia K-562 cell lines. *Asian Pac. J. Trop. Biomed.* 2017, 7, 14–19. [CrossRef]

111. Ávila-Román, J.; García-Gil, S.; Rodriguez-Luna, A.; Motilva, V.; Talero, E. Anti-inflammatory and anticancer effects of microalgal carotenoids. *Mar. Drugs* 2021, 19, 531. [CrossRef]

112. Sun, Y.; Wang, Z.; Wang, L.; Wang, L.; Zang, C.; Sun, L. The effect and mechanisms of proliferative inhibition of crocin in human leukemia jurkat cells. *West Indian Med. J.* 2015, 64, 473. [CrossRef]

113. Veisi, A.; Akbari, G.; Mard, S.A.; Badfar, G.; Zarezade, V.; Mirshekar, M.A. Role of crocin in several cancer cell lines: An updated review. *Iran. J. Basic Med. Sci.* 2020, 23, 3.

114. Colapietro, A.; Mancini, A.; D’Alessandro, A.M.; Festuccia, C. Crocetin and crocin from saffron in cancer chemotherapy and chemoprevention. *Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem. Anti Cancer Agents)* 2019, 19, 38–47. [CrossRef]
116. Kaushik, N.; Kumar, N.; Kim, C.H.; Kaushik, N.K.; Choi, E.H. Dielectric barrier discharge plasma efficiently delivers an apoptotic response in human monocytic lymphoma. *Plasma Processes Polym.* **2014**, *11*, 1175–1187. [CrossRef]

117. Chen, F.; Hu, J.; Liu, P.; Li, J.; Wei, Z.; Liu, P. Carotenoid intake and risk of non-Hodgkin lymphoma: A systematic review and dose-response meta-analysis of observational studies. *Ann. Hematol.* **2017**, *96*, 957–965. [CrossRef]

118. Li, S.; Zhu, X.; Zhu, L.; Hu, X.; Wen, S. Associations between serum carotenoid levels and the risk of non-Hodgkin lymphoma: A case–control study. *Br. J. Nutr.* **2020**, *124*, 1311–1319. [CrossRef]

119. Bozorgpour, A.; Azad, R.; Showkatian, E.; Sulaiman, A. Multi-scale regional attention deeplab3+: Multiple myeloma plasma cells segmentation in microscopic images. *arXiv* 2021, arXiv:210506238.

120. Hoshyar, R.; Mollaei, H. A comprehensive review on anticancer mechanisms of the main carotenoid of saffron, crocin. *J. Pharm. Pharmacol.* **2017**, *69*, 1419–1427. [CrossRef] [PubMed]

121. Qian, T.; Cui, L.; Liu, Y.; Cheng, Z.; Quan, L.; Zeng, T.; Huang, W.; Dai, Y.; Chen, J.; Liu, L. High expression of chaperonin-containing TCP1 subunit 3 may induce dismal prognosis in multiple myeloma. *Pharm. J.* **2020**, *20*, 563–573. [CrossRef] [PubMed]

122. Raza, S.H.A.; Naqvi, S.R.Z.; Abdelnour, S.A.; Schreurs, N.; Mohammedsaleh, Z.M.; Khan, I.; Shater, A.F.; Abd El-Hack, M.E.; Khafaga, A.F.; Quan, G.; et al. Beneficial effects and health benefits of Astaxanthin molecules on animal production: A review. *Res. Vet. Sci.* **2021**, *138*, 69–78. [CrossRef]